IGHE and polyp: Patients with signs of type 2 inflammation, such as elevated levels of tissue and peripheral blood eosinophils (polyp tissue eosinophils ≥10/high-power field or blood eosinophils ≥150 cells/mcL) and serum IgE (total IgE ≥100 international units/ml), should be considered for biologic therapy treatment of CRSwNP, according to current guidelines (44, 45).